Owner and operator of biotechnology firm intended to eradicate infectious diseases using a novel, patented technology platform. The company's platform addresses the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases like Tamiflu alternative for influenza, emerging infectious diseases and biodefense, enabling doctors to provide effective treatment for influenza, creating a powerful alternative to Tamiflu and rabies.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Angel (individual) | 05-Oct-2018 | $875K | 000.00 | Completed | Clinical Trials - Phase 1 | |
1. Capitalization | 01-Jan-2018 | 0000 | 0000 | Completed | Clinical Trials - Phase 1 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
David Horn MD | Co-Founder & Chief Executive Officer | ||
Jean-Pierre Gagnon | Co-Founder, Senior Vice President & Board Member |
Name | Representing | Role | Since |
---|---|---|---|
Jean-Pierre Gagnon | Mid-Atlantic BioTherapeutics | Co-Founder, Senior Vice President & Board Member | 000 0000 |
Julian Chick Ph.D | Mid-Atlantic BioTherapeutics | Board Member | 000 0000 |
Michael Goldblatt Ph.D | Mid-Atlantic BioTherapeutics | Board Member | 000 0000 |